Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com
News announced during the 37th J.P. Morgan Healthcare Conference (#JPM19): Dublin medtech HealthBeacon raises $12m in a Series A round
Reporter: Gail S. Thornton
HealthBeacon’s Smart Sharps system helps patients adhere to their medication schedule. The company was founded by Jim Joyce and Kieran Daly in 2013, and opened offices in Boston in 2017. The digital platform, which last year received vital FDA clearance for the US market, not only ensures that patients keep up with their injectable treatments, but also allows them to dispose of medication in a safe way, and keeps carers up to date with the patients’ progress.
Published January 8, 2019 by John Kennedy, Silicon Republic.
From left: Co-founders Kieran Daly and Jim Joyce. Image: HealthBeacon
With funding and FDA approval under its belt, this Dublin tech start-up has plans to help patients stick to their medication schedule.
Dublin and Boston digital health company HealthBeacon has raised $12m in a Series A investment round that brings total investment in the company to almost $15m.
The round was organised by HealthBeacon and Cantor Fitzgerald, led by Oyster Capital and Elkstone Partners, and the investment syndicate included Quorndon Capital and Cantor Fitzgerald’s private client group. Earlier investors in HealthBeacon include Enterprise Ireland, BVP and a range of angel investors.
‘I know with confidence as to whether my patients are adhering to their treatment strategy’ – DOUG VEALE
“Cantor has a major focus on life sciences and on digital health, and we have every confidence that CEO and co-founder Jim Joyce has created a true sector leader in HealthBeacon,” said Liam Kiely, director of Cantor Fitzgerald.
The announcement was made in San Francisco at the JPMorgan Chase Biotech Showcase. The funding comes on the back of rapid global expansion of the FDA-cleared HealthBeacon Smart Sharps technology.
The right stuff
Dublin-based HealthBeacon’s Smart Sharps system helps patients adhere to their medication schedule. The company was founded by Jim Joyce and Kieran Daly in 2013, and opened offices in Boston in 2017.
The digital platform, which last year received vital FDA clearance for the US market, not only ensures that patients keep up with their injectable treatments, but also allows them to dispose of medication in a safe way, and keeps carers up to date with the patients’ progress.
The funding from this Series A will be used to launch its Smart Sharps system in the US and to develop its portfolio of medical adherence tools for high-value medications.
In 2017, HealthBeacon revealed plans to create 20 new jobs in Dublinin roles spanning IT, software development, project management and customer service. As of today, HealthBeacon operates in 10 markets and has tracked more than 200,000 home-based injections, making it one of the largest global deployments of a medical adherence device. Today, HealthBeacon employs more than 30 people and plans to double the team over the next 18 months.
The addressable market for injectable medications has reached nearly $50bn, according to the company. The Smart Sharps bin system by HealthBeacon has made it easier for patients using injectable medications to stay on track with their treatment. This has resulted in improved patient medication adherence, driving patient care.
In December, HealthBeacon was named eHealth Innovation of the Year by the Irish Medtech Association.
“I’ve been using the HealthBeacon for over two years, and their Smart Sharps bin has had a profound impact on how patients manage their treatment,” said Doug Veale, professor of rheumatology at St Vincent’s Hospital in Dublin.
“I know with confidence as to whether my patients are adhering to their treatment strategy.”
Editor John Kennedy is an award-winning technology journalist.
e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point – Updated on 4/2/2018
EXPERTS, AUTHORS, WRITERS (EAWs) CURATE ORIGINAL SCIENTIFIC ARTICLES
EXPERTS, AUTHORS, WRITERS (EAWs) REPORT on Scientific Breakthroughs or Agendas of Conferences of TIGHTEST relevance to our Journal domain of Expertise:
Our DOMAINS in Scientific Media
Pharmaceutical: Biologics, Small Molecules, Diagnostics
Life Sciences: Genomics and Cancer Biology
III. Patient-centered Medicine: Focus on #1: Cardiovascular, #2: Cancer, #3: Physiology Metabolomics, Immunology
Biomedicine, BioTech, and MedTech (Medical Devices)
HealthCare: Patient-centered Medicine and Personalized/Precision Medicine
EXPERTS Editors, — ONLY — Medical Doctors, PhDs, MD/PhDs, PharmDs — are creating a CREATIVE EXPERTISE DRIVENelectronic Table of Contents (eTOCs) — ONE OF A KIND per each volume — NOT IN EXISTENCE ANYWHERE ON THE INTERNET — not derived from consultation with other textbooks — not in existence in any public domain source
Step #3:
ALL our articles adhere to the strictestREFERENCE CITATION AND SOURCE CITATION STANDARDS
EXPERTS Editors of our e-Books, are ALL — Medical Doctors, PhDs, MD/PhDs, PharmDs — ONLY — these requirements fulfilled AND a substantial LIST OF PUBLICATIONS entitles EAWs to become Editors and are granted the level of privilege of editing the written articles of other EAWs – the role of Editors.
EXPERTS Editors of our e-Books, are ALL — Medical Doctors, PhDs, MD/PhDs, PharmDs — ONLY they SELECT ARTICLES FOR INCLUSION in e-Books from our Archived REPOSITORY
On 8/11/2016the Web site statistics included the following data:
4,815 Scientific Articles,
491 Research Categories (Journal Ontology), and
9,433 Scientific Tags
7,261 Scientific COmments
Step #6:
All volumes are converted to .mobi format for KINDLE platform
Step #7:
All converted volumes are PROOFREAD BY TWO EDITORS
Step #8:
Editor-in-Chief is the ONLY authority authorizing the UPLOAD to Amazon.com of a ready to be published e-Book
Thus, we have published EIGHT e-Books in MEDICINE and Life Sciences
ALL our e-Books contain Expert driven eTOCs demonstrating an ORIGINAL thought process and represent the FRONTIER of the STATE of Science in every case.
Advances in Gene Editing and Gene Silencing | September 20-21, 2016 | Boston, MA
Reporter: Aviva Lev-Ari, PhD, RN
2.1.5.28 Advances in Gene Editing and Gene Silencing | September 20-21, 2016 | Boston, MA, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair
KEYNOTE SESSION: GENOME EDITING FOR IN VIVO APPLICATIONS
Part 1 (of a two-part conference) will cover the use of CRISPR/Cas9 and RNAi for identifying new drug targets and therapies. It will bring together experts from all aspects of basic science and clinical research to talk about how and where gene editing and RNAi can be best applied. What are the different tools that can be used and what are their strengths and limitations? How does the CRISPR/Cas system compare to RNAi and other gene editing tools, such as Transcription Activator-like Effector Nucleases (TALENs) and zinc finger nucleases (ZFNs), and do they have any complementary uses? Scientists and clinicians from pharma/biotech as well as from academic and government labs will share their experiences leveraging the utility of gene editing for target discovery, disease modeling, and for creating cell and viral therapies. Learn more atDiscoveryOnTarget.com/RNAi-screens-functional-genomics
Keynote Session: Genome Editing for InVivo Applications
AAV for Gene Therapy and Genome Editing James Wilson, M.D., Ph.D., Professor, Department of Pathology and Laboratory Medicine, Perelman School of Medicine; Director, Orphan Disease Center and Director, Gene Therapy Program, University of Pennsylvania In vivo delivery of nucleic acid therapeutics remains the primary barrier to success. My lab has focused on the use of vectors based on adeno-associated virus (AAV) for achieving success in pre-clinical and clinical applications of gene replacement therapy. Most of the current academic and commercial applications of in vivo gene replacement therapy are based on endogenous AAVs we discovered as latent viral genomes in primates. These vectors are reasonably safe and efficient for application of gene replacement therapy. The emergence of genome editing methods has suggested more precise and effective methods to treat inherited diseases in which genes are silenced or mutations are corrected. AAV vectors have been the most efficient platform for achieving genome editing in vivo. We will review our attempts to achieve therapeutic genome editing in animal models of liver disease using AAV.
Using CRISPR/Cas to Target and Destroy Viral DNA Genomes Bryan R. Cullen, Ph.D., James B. Duke Professor of Molecular Genetics and Microbiology and Director, Center for Virology, Duke University
A number of pathogenic human DNA viruses, including HBV, HIV-1 and HSV1, cause chronic diseases in humans that remain refractory to cure, though these diseases can be controlled by antivirals. In addition the DNA virus HPV causes tumors that depend on the continued expression of viral genes. Here, I will present data demonstrating that several of these viruses can be efficiently cleaved and destroyed using viral vectors that express Cas9 and virus-specific guide RNAs, thus providing a potential novel approach to treatment.
Targeted Endonucleases as Antiviral Agents: Promises and Pitfalls Keith R. Jerome, M.D., Ph.D., Member, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center; Professor and Head, Virology Division, Department of Laboratory Medicine, University of Washington
Genome editing offers the prospect of cure for infections such as HIV, hepatitis B virus, herpes simplex, and human papillomavirus, by disruption of essential viral nucleic acids or the human genes encoding receptors needed for viral entry. This talk will highlight the most recent laboratory data and the challenges still ahead in bringing this technology to the clinic.
Nucleic Acid Delivery Systems for RNA Therapy and Gene Editing Daniel Anderson, Ph.D., Professor, Department of Chemical Engineering, Institute for Medical Engineering & Science, Harvard-MIT Division of Health Sciences & Technology and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
High throughput, combinatorial approaches have revolutionized small molecule drug discovery. Here we describe our high throughput methods for developing and characterizing RNA delivery and gene editing systems. Libraries of degradable polymers and lipid-like materials have been synthesized, formulated and screened for their ability to deliver RNA, both in vitro and in vivo. A number of delivery formulations have been developed with in vivo efficacy, and show potential applications for the treatment of genetic diseases, viral infections and cancers.
PANEL DISCUSSION: CRISPR/Cas: A Realistic and Practical Look at What the Future Could Hold
Moderator: Bryan R. Cullen, Ph.D., James B. Duke Professor of Molecular Genetics and Microbiology and Director, Center for Virology, Duke University
Participants: Session Speakers
Each speaker will spend a few minutes sharing their viewpoints and experiences on where things stand with using the CRISPR/Cas system for in vivo applications. Attendees will have an opportunity to ask questions and share their opinions.
About the Conference
Cambridge Healthtech Institute’s 13th annual two-part conference on Advances in Gene Editing and Gene Silencing will cover the latest in the use of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9-based gene editing and RNA interference (RNAi) for use in drug discovery and for developing novel drug therapies.
For sponsorship and exhibit sales information including podium presentation opportunities, contact:
Jon Stroup | T: +1 781-972-5483 | E: jstroup@healthtech.com
Recommended All Access Package:
Includes access to 1 Symposium and 2 Conferences
Cambridge Healthtech Institute, 250 First Avenue, Suite 300, Needham, MA, USA Tel: 781-972-5400 | Fax: 781-972-5425 | www.healthtech.com
This email is being sent to sjwilliamspa@comcast.net for marketing purposes. If it is not of interest to you, please disregard and we apologize for any inconvenience this may have caused.
4:00 A New Era of Personalized Therapy: Using Tumor Neoantigens to Unlock the Immune System
Matthew J. Goldstein, M.D., Ph.D., Director, Translational Medicine, Neon Therapeutics, Inc.
Neon Therapeutics, Inc. launched in 2015 to focus on advancing neoantigen biology to improve cancer patient care. A neoantigen-based product engine will allow Neon to develop further treatment modalities including next-generation vaccines and T cell therapies targeting both personalized as well as shared neoantigens. The company’s first trial will launch later this year investigating the combination of a personalized, vaccine with nivolumab in advanced Melanoma, NSCLC, and Bladder Cancer.
4:30 Emerging Innate Immune Targets for Enhancing Adaptive Anti-Tumor Responses
Michael Rosenzweig, Ph.D., Executive Director, Biology-Discovery, IMR Early Discovery, Merck Research Laboratories
Novel cancer immunotherapies targeting T cell checkpoint proteins have emerged as powerful tools to induce profound, durable regression and remission of many types of cancer. Despite these advances, multiple studies have demonstrated that not all patients respond to these therapies, and the ability to predict which patients may respond is limited. Harnessing the innate immune system to augment the adaptive anti-tumor response represents an attractive target for therapy, which has the potential to enhance both the percentage and rate of response to checkpoint blockade.
5:00 Reading Tea Leaves:
The Dilemma of Prediction and Prognosis in Immunotherapy
Morganna Freeman, D.O., Associate Director, Melanoma & Cutaneous Oncology Program, The Angeles Clinic and Research Institute
With the rapid expansion of immunotherapeutics in oncology, scientifically significant advances have been made with both the depth and duration of antitumor responses. However, not all patients benefit, or quickly relapse, thus much scientific inquiry has been devoted to appropriate patient selection and how such obstacles might be overcome. While more is known about potential biomarkers, accurate prognostication persists as a knowledge gap, and efforts to bridge it will be discussed here.
Personalized Immunotherapy | The Immuno-Oncology Summit
August 30-31, 2016 | Marriott Long Wharf Hotel – Boston, MA
Fueled with advances in genomic technologies, personalized oncology promises to innovate cancer therapy and target the previously undruggable space. Developments in immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies, as well as biomarker-driven immuno-oncology clinical trials, are enabling the next generation of cancer therapy. Cambridge Healthtech Institute’s Inaugural Personalized Immunotherapy meeting brings together clinical immuno-oncologists and thought leaders from pharmaceutical and biotech companies, and leading academic teams to share research and case studies in implementing patient-centric approaches to using the immune system to beat cancer.
TUMOR NEOANTIGENS FOR PERSONALIZED IMMUNOTHERAPY
Basics of Personalized Immunotherapy: What Is a Good Antigen?
Pramod K. Srivastava, M.D., Ph.D., Professor, Immunology and Medicine, Director, Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine
Novel Antibodies against Immunogenic Neoantigens
Philip M. Arlen, M.D., President & CEO, Precision Biologics, Inc.
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Luis Alberto Diaz, M.D., Associate Professor, Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
PERSONALIZED IMMUNOTHERAPY WITH CANCER VACCINES
Cancer Vaccines in the Era of Checkpoint Inhibitors
Keith L. Knutson, Ph.D., Professor, Immunology, Mayo Clinic
Developing Therapeutic Cancer Vaccine Strategies for Prostate Cancer
Ravi Madan, M.D., Clinical Director, Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health
Getting Very Personal: Fully Individualized Tumor Neoantigen-Based Vaccine Approaches to Cancer Therapy
Karin Jooss, Ph.D., CSO, Gritstone Oncology
Approaches to Assess Tumor Mutation Load for Selecting Patients for Cancer Immunotherapy
John Simmons, Ph.D., Manager, Research Services, Personal Genome Diagnostics
In situ Vaccination for Lymphoma
Joshua Brody, M.D., Director, Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai
Immunotherapy Using Ad5 [E1-, E2b-] Vector Vaccines in the Cancer MoonShot 2020 Program
Frank R. Jones, Ph.D., Chairman & CEO, Etubics Corporation
PERSONALIZED CELL THERAPY
Integration of Natural Killer-Based Therapy into the Treatment of Lymphoma
Andrew M. Evens, D.O., Professor and Chief, Hematology/Oncology, Tufts University School of Medicine; Director, Tufts Cancer Center
Dendritic Cells: Personalized Cancer Vaccines and Inducers of Multi-Epitope-Specific T Cells for Adoptive Cell Therapy
Pawel Kalinski, M.D., Ph.D., Professor, Surgery, Immunology, and Bioengineering, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute
Mesothelin-Targeted CAR T-Cell Therapy for Solid Tumors
Prasad S. Adusumilli, M.D., FACS, Deputy Chief of Translational & Clinical Research, Thoracic Surgery, Memorial Sloan-Kettering Cancer Center
Synthetic Regulation of T Cell Therapies Adds Safety and Enhanced Efficacy to Previously Unpredicted Therapies
David M. Spencer, Ph.D., CSO, Bellicum Pharmaceuticals
Long-Term Relapse-Free Survival of Patients with Acute Myeloid Leukemia (AML) Receiving a Telomerase- Engineered Dendritic Cell Immunotherapy
Jane Lebkowski, Ph.D., President & CSO, Research and Development, Asterias Biotherapeutics
Activated and Exhausted Tumor Infiltrating B Cells in Non-Small Cell Lung Cancer Patients Present Antigen and Influence the Phenotype of CD4 Tumor Infiltrating T Cells
Tullia Bruno, Ph.D., Research Assistant Professor, Immunology, University of Pittsburgh
About the Immuno-Oncology Summit
CHI’s 4th Annual Immuno-Oncology Summit has been designed to support a coordinated effort by industry players to bring commercial immunotherapies and immunotherapy combinations through clinical development and into the market. This weeklong, nine-meeting set will include topics ranging from early discovery through clinical development as well as emerging areas such as oncolytic virotherapy. Overall, this event will provide a focused look at how researchers are applying new science and technology in the development of the next generation of effective and safe immunotherapies.
Cambridge Healthtech Institute, 250 First Avenue, Suite 300, Needham, MA 02494 healthtech.com
Tel: 781-972-5400 | Fax: 781-972-5425
This email is being sent to sjwilliamspa@comcast.net. This email communication is for marketing purposes. If it is not of interest to you, please disregard and we apologize for any inconvenience this may have caused.
Visit www.chicorporate.com/corporate_unsubscribe.aspx to update usage.
Adverse drug events such as cardiotoxicity, hepatotoxicity and other organ toxicities, keep surfacing in the clinic and idiosyncratic drug toxicity continues to haunt the drug development process. So what are scientists and clinicians doing to make sure that compounds fail early and cheaply? New screening technologies such as, in vitro assays and in vivo models continue to be developed, but are the right tools being used at the right time to predict and detect adverse events? Cambridge Healthtech Institute’s ninth annual conference on Models to Approaches, looks at the scientific and technological progress being made to better predict drug related toxicities at the preclinical stage, and avoid unexpected and costly findings in the clinic. What assays and models are being used, how reliable and predictable is the data, and how is this information impacting decisions before compounds are tested in patients? Hear experiences shared by experts and join the interactive sessions and panel discussions on issues related to drug toxicity.
Register Now! [Register by March 4th and save up to $400]
Agenda-at-a-Glance
Day 1
DRUG TRANSPORTERS AND THEIR ROLE IN DRUG TOXICITY
Transporter-Mediated Drug Interactions with Endobiotics, Toxins and Nutrients Adrian Ray, Ph.D., Senior Director, Department of Drug Metabolism, Gilead Sciences, Inc.
Combination of Top-Down and Bottom-Up Strategy to Elucidate Mechanistic Roles of Transporters in Organ Toxicity Yurong Lai, Ph.D., Senior Principal Scientist, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb In vitro Human Intestinal Tissue Model to Assess and Predict Drug-Induced-GI Damage Seyoum Ayehunie, Ph.D., Vice President, Immunological Systems, MatTek Corporation
Assessing Off-Target Drug Activities by Transcription Factor Profiling in FACTORIAL™ Assays Sergei Makarov, Ph.D., CEO, Attagene
UNDERSTANDING TRANSLATIONAL CHALLENGES AND INTERPRETING SAFETY GUIDELINES
The Importance of Reverse Translation for Preclinical Off-Target Mitigation Laszlo Urban, M.D., Ph.D., Global Head, Preclinical Secondary Pharmacology, Novartis Institutes for BioMedical Research, Inc.
Moving beyond the S6(R1): A Snapshot of Toxicity & Safety Pharmacology Tools to Evaluate Biotherapeutics Susan M.G. Goody, Ph.D., Senior Principal Scientist, Global Safety Pharmacology, Pfizer, Inc.
Presentation to be Announced
Luncheon Presentation: CiPA: How Comprehensive Does It Have to Be James Kramer, Ph.D., Principal Scientist, Discovery, Charles River
IN VIVO TECHNIQUES FOR MONITORING DRUG TOXICITY
A Disruption of Autonomic Balance: Use of Heart Rate Variability (HRV) in Cardiovascular Safety Pharmacology Carrie Northcott, Ph.D., Senior Principal Scientist, Global Safety Pharmacology, Pfizer Inc.
Whole-Body Imaging of Drug-Induced Toxicity Ming Zhao, Ph.D., Associate Professor, Feinberg School of Medicine, Northwestern University
NEW IN VITRO SCREENING APPROACHES FOR SAFETY TESTING
Combination of Screening Assays for Assessing Drug-Induced Liver Injury in Humans Christoph Funk, Ph.D., Vice Director, Pharmaceutical Sciences, F. Hoffmann-La Roche
In vitro Approach to Classify Drugs According to Their Idiosyncratic, Drug-Induced Liver Injury Liability Robert A. Roth, Ph.D., DABT, Professor of Pharmacology and Toxicology and Director, Graduate Program in Environmental and Integrative Toxicological Sciences, Michigan State University
Generation of Complex Disease Phenotypes in 3D Bioprinted Human Liver Tissues for the Assessment of Drug-Induced Injury Leah Norona, Doctoral Candidate Curriculum in Toxicology, University of North Carolina at Chapel Hill
Drug-Induced Vascular Injury (DIVI)- Historical Review of Non-Clinical DIVI and Development of an Early Screening Strategy Todd Wisialowski, MS, Associate Research Fellow, Global Safety Pharmacology, Pfizer Inc.
Day 2
INTERACTIVE BREAKOUT DISCUSSION GROUPS
TOPIC: Safety Assessments for Biologics Moderator: Susan M.G. Goody, Ph.D., Senior PrincipalScientist, Global Safety Pharmacology, Pfizer, Inc.
TOPIC: Translation of Preclinical Findings to Clinic Moderators: Carrie Northcott, Ph.D., Senior Principal Scientist, Global Safety Pharmacology, Pfizer Inc. Ming Zhao, Ph.D., Associate Professor, Feinberg School of Medicine, Northwestern University
TOPIC: Using iPSC for Drug Safety Screening Moderators: Paul W. Burridge, Ph.D., Assistant Professor, Department of Pharmacology, Center for Pharmacogenomics, Northwestern University Feinberg School ofMedicine Xi Yang, Ph.D., DABT, Principal Investigator, Division of Systems Biology, National Center for Toxicological Research (NCTR), U.S. FDA
TOPIC: Key Issues Related to Drug Transporters in a Pharma R&D Setting Moderator: Christoph Funk, Ph.D., Vice Director, Pharmaceutical Sciences, F. Hoffmann La-Roche
USE OF iPS CELLS FOR DRUG TOXICITY SCREENING
Utilization of iPSCs in Developing Human-on-a-Chip Systems for Phenotypic Screening Applications James J. Hickman, Ph.D., Founding Director, NanoScience Technology Center; Professor, Nanoscience Technology, Chemistry, Biomolecular Science, Material Science and Electrical Engineering, University of Central Florida
Human-Induced Pluripotent Stem Cells Recapitulate Breast Cancer Patients’ Predilection to Doxorubicin-Induced Cardiotoxicity Paul W. Burridge, Ph.D., Assistant Professor, Department of Pharmacology, Center for Pharmacogenomics, Northwestern University Feinberg School of Medicine
Utilization of Induced Pluripotent Stem Cells to Understand Tyrosine Kinase Inhibitors (TKIs)-Induced Hepatotoxicity Qiang Shi, Ph.D., Principal Investigator, Division of Systems Biology, National Center for Toxicological Research (NCTR), U.S. FDA
UNDERSTANDING MECHANISMS TO BETTER PREDICT DRUG TOXICITY
Predict Tyrosine Kinase Inhibitors (TKIs)-Induced Cardiotoxicity Using Induced Pluripotent Stem Cell-Derived Cardiomyocytes Xi Yang, Ph.D., DABT, Principal Investigator, Division of Systems Biology, National Center for Toxicological Research (NCTR), U.S. FDA
Prediction of Transporter-Related Drug-Induced Liver Injury (DILI) Using Integrated Approaches Mingxiang Liao, Ph.D., Senior Scientist I, DMPK, Takeda Pharmaceutical Intl. Company
Bridging Luncheon Presentation: Case Studies in Cardiac and Neuro Safety / Toxicity Assessment Using Human iPSC-Derived Cell Systems Greg Luerman, Ph.D., Head, Applications Development, Axiogenesis Inc.
Plenary Sessions
June 16, 1:45-2:45 pm
PLENARY KEYNOTE PRESENTATIONS:
INSIGHTS ON INNOVATIVE APPROACHES TO TRANSFORM DRUG DISCOVERY
This year’s Plenary Keynote Presentations feature two prominent thought-leaders who are playing an important role in innovating drug discovery. They share their experiences and their perspectives on what has changed and what can be changed to improve preclinical research, help translate preclinical findings to the clinic, and to foster effective communication and collaboration. Attendees will have an opportunity to ask questions and gain valuable insights from their learnings.
Keynote Speakers: Anthony J. Coyle Ph.D., Chief Scientific Officer and Senior Vice President, Centers for Therapeutic Innovation, Pfizer Inc.
James Wilson, M.D., Ph.D., Professor, Department of Pathology and Laboratory Medicine, Perelman School of Medicine; Director, Orphan Disease Center and Director, Gene Therapy Program, University of Pennsylvania
June 16, 2:45-3:30 pm
PLENARY KEYNOTE PANEL:
INSIGHTS ON INNOVATIVE TECHNOLOGIES ENABLING PRECLINICAL RESEARCH
This year’s Plenary Keynote Panel features a group of technical experts from life science technology and service companies, who share their perspectives on various trends and tools that will likely change the way in which we traditionally approach preclinical drug discovery and development. Attendees will have an opportunity to ask questions and understand the impact of recent technical advances.
Panelists: Matt Gevaert, Ph.D., CEO and Co-founder, KIYATEC
Amit Vasanji, Ph.D., CTO & CSO, ImageIQ
Biographies:
Dr. Anthony Coyle is the founding CSO of the Centers for Therapeutic Innovation (CTI) and is responsible for CTI’s strategy and scientific direction. Before leading CTI, Dr. Coyle was the Vice President and Global Head of Respiratory, Inflammation, and Autoimmunity Research at MedImmune Biologics, a Division of AstraZeneca. At MedImmune, Dr. Coyle advanced a biologic portfolio from discovery to Phase II in the areas of respiratory and autoimmune diseases, specifically targeting lupus, asthma and COPD. Prior to his work at MedImmune, Dr. Coyle was Director of Research at Millennium Pharmaceuticals, where he led a group responsible for the identification of novel target genes, as well as for late stage lead optimization and delivery of both small-molecule and biologic development candidates. Dr. Coyle has been Associate Professor in the Department of Pathology and Experimental Therapeutics at McMaster University in Ontario since 1992. He has authored more than 200 manuscripts. Dr. Coyle holds a BSc (with honors) and a Ph.D. from Kings College, University of London. Dr. Coyle is a member of the scientific board for the Alliance for Lupus Research, the C4 NCATS consortium and the Boston Children’s Hospital Technology Fund Advisory Board.
Dr. James M. Wilson is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has led an effort to develop the field of gene therapy. Dr. Wilson began his work in gene therapy during his graduate studies at the University of Michigan over 30 years ago. He then moved to Boston to do a residency in Internal Medicine at the Massachusetts General Hospital and continued his work in gene therapy at MIT. He created the first and largest academic-based program in gene therapy after being recruited to University of Pennsylvania in 1993. He initially focused on the clinical translation of existing gene transfer technologies but soon redirected his efforts to the development of second and third generation gene transfer platforms; the first of which was licensed to a biotechnology company he founded that resulted in the first, and only, commercially approved gene therapy in the western hemisphere. More recently, his laboratory discovered a family of viruses from primates that could be engineered to be very effective gene transfer vehicles. These so called “vectors” have become the technology platform of choice and have set the stage for the recent resurgence of the field of gene therapy. Dr. Wilson has also been active in facilitating the commercial development of these new gene therapy platforms through the establishment of several biotechnology companies. Throughout his career, the focus of Dr. Wilson’s research has been rare inherited diseases, ranging from cystic fibrosis to dyslipidemias to a variety of metabolic disorders. Dr. Wilson has published over 550 papers, reviews, commentaries and editorials in the peer-reviewed literature and is an inventor on over 117 patents.
Dr. Matthew (Matt) Gevaert is the CEO of KIYATEC Inc., a life sciences company in Greenville, SC. KIYATEC specializes in ex vivo 3D cell culture and tissue systems that more accurately replicate in vivo human biology and function, with a focus on methods to accurately predict individual cancer patients’response to drugs by culturing and treating live patient derived primary cells. Dr. Gevaert co-founded the company and has served as CEO since 2007. Possessing a background which combines both business and technology, before his role at KIYATEC Dr. Gevaert led the commercialization of Clemson University’s biomedical and biotechnology intellectual property portfolio for nearly 5 years, working with both entrepreneurial start-ups and large, industry leading corporations. He has previous experience with Merck, 3M and Dow Chemica l, and has been published in Science magazine and the journal of the US National Academy of Engineering. Currently he serves as a board member of SCBIO, the state of South Carolina’s life science industry organization, and a board member of NEXT, which provides entrepreneur services and infrastructure to high-growth ventures in Greenville and Upstate South Carolina. Dr. Gevaert grew up the fifth of six children on a farm in Ontario, Canada and graduated from the University of Waterloo with a bachelor’s degree in Applied Chemistry. He also holds a master’s degree and a doctorate in Bioengineering from Clemson University. He maintains current appointments as adjunct professor in the Clemson University Department of Bioengineering and as a lecturer in the Clemson MBA in Entrepreneurship & Innovation.
Dr. Amit Vasanji has over 17 years of experience with basic and clinical research image acquisition, processing, analysis, visualization and biomedical software engineering. He was the founder of Cleveland Clinic’s Biomedical Imaging and Analysis Center, and served as its Executive Director. During his tenure at the Cleveland Clinic, he authored over 50 publications — many in high impact journals, participated in the writing of numerous federally funded grants, served as a consultant and/or co-investigator on many federal, state, corporate, and institutional grants, presented at national scientific meetings, and won various awards for innovation and service. Dr. Vasanji received a BS in Biomedical Engineering from the University of Miami, and a Ph.D. in biomedical engineering from Case Western Reserve University
Track 9 Pharmaceutical R&D Informatics: Collaboration, Data Science and Biologics @ BioIT World, April 29 – May 1, 2014 Seaport World Trade Center, Boston, MA
Reporter: Aviva Lev-Ari, PhD, RN
April 30, 2014
Big Data and Data Science in R&D and Translational Research
10:50 Chairperson’s Remarks
Ralph Haffner, Local Area Head, Research Informatics, F. Hoffmann-La Roche AG
11:00 Can Data Science Save Pharmaceutical R&D?
Jason M. Johnson, Ph.D., Associate Vice President,
Scientific Informatics & Early Development and Discovery Sciences IT, Merck
Although both premises – that the viability of pharmaceutical R&D is mortally threatened and that modern “data science” is a relevant superhero – are
suspect, it is clear that R&D productivity is progressively declining and many areas of R&D suboptimally use data in decision-making. We will discuss
some barriers to our overdue information revolution, and our strategy for overcoming them.
11:30 Enabling Data Science in Externalized Pharmaceutical R&D
Sándor Szalma, Ph.D., Head, External Innovation, R&D IT,
Janssen Research & Development, LLC
Pharmaceutical companies have historically been involved in many external partnerships. With recent proliferation of hosted solutions and the availability
of cost-effective, massive high-performance computing resources there is an opportunity and a requirement now to enable collaborative data science. We
discuss our experience in implementing robust solutions and pre-competitive approaches to further these goals.
12:00 pm Co-Presentation: Sponsored by
Collaborative Waveform Analytics: How New Approaches in Machine Learning and Enterprise Analytics will Extend Expert Knowledge and Improve Safety Assessment
Tim Carruthers, CEO, Neural ID
Scott Weiss, Director, Product Strategy, IDBS
Neural ID’s Intelligent Waveform Service (IWS) delivers the only enterprise biosignal analysis solution combining machine learning with human expertise. A collaborative platform supporting all phases of research and development, IWS addresses a significant unmet need, delivering scalable analytics and a single interoperable data format to transform productivity in life sciences. By enabling analysis from BioBook (IDBS) to original biosignals, IWS enables users of BioBook to evaluate cardio safety assessment across the R&D lifecycle.
12:15 Building a Life Sciences Data
Sponsored by
Lake: A Useful Approach to Big Data
Ben Szekely, Director & Founding Engineer,
Cambridge Semantics
The promise of Big Data is in its ability to give us technology that can cope with overwhelming volume and variety of information that pervades R&D informatics. But the challenges are in practical use of disconnected and poorly described data. We will discuss: Linking Big Data from diverse sources for easy understanding and reuse; Building R&D informatics applications on top of a Life Sciences Data Lake; and Applications of a Data Lake in Pharma.
12:40 Luncheon Presentation I:
Sponsored by
Chemical Data Visualization in Spotfire
Matthew Stahl, Ph.D., Senior Vice President,
OpenEye Scientific Software
Spotfire deftly facilitates the analysis and interrogation of data sets. Domain specific data, such as chemistry, presents a set of challenges that general data analysis tools have difficulty addressing directly. Fortunately, Spotfire is an extensible platform that can be augmented with domain specific abilities. Spotfire has been augmented to naturally handle cheminformatics and chemical data visualization through the integration of OpenEye toolkits. The OpenEye chemistry extensions for Spotfire will be presented.
1:10 Luncheon Presentation II
1:50 Chairperson’s Remarks
Yuriy Gankin, Ph.D., Co. Founder and CSO, GGA Software Services
1:55 Enable Translational Science by Integrating Data across the R&D Organization
Christian Gossens, Ph.D., Global Head, pRED Development Informatics Team,
pRED Informatics, F. Hoffmann-La Roche Ltd.
Multi-national pharmaceutical companies face an amazingly complex information management environment. The presentation will show that
a systematic system landscaping approach is an effective tool to build a sustainable integrated data environment. Data integration is not mainly about
technology, but the use and implementation of it.
2:25 The Role of Collaboration in Enabling Great Science in the Digital Age: The BARD Data Science Case Study
Andrea DeSouza, Director, Informatics & Data Analysis,
Broad Institute
BARD (BioAssay Research Database) is a new, public web portal that uses a standard representation and common language for organizing chemical biology data. In this talk, I describe how data professionals and scientists collaborated to develop BARD, organize the NIH Molecular Libraries Program data, and create a new standard for bioassay data exchange.
May 1. 2014
BIG DATA AND DATA SCIENCE IN R&D AND TRANSLATIONAL RESEARCH
10:30 Chairperson’s Opening Remarks
John Koch, Director, Scientific Information Architecture & Search, Merck
10:35 The Role of a Data Scientist in Drug Discovery and Development
A major challenge in drug discovery and development is finding all the relevant data, information, and knowledge to ensure informed, evidencebased
decisions in drug projects, including meaningful correlations between preclinical observations and clinical outcomes. This presentation will describe
where and how data scientists can support pharma R&D.
11:05 Designing and Building a Data Sciences Capability to Support R&D and Corporate Big Data Needs
Shoibal Datta, Ph.D., Director, Data Sciences, Biogen Idec
To achieve Biogen Idec’s strategic goals, we have built a cross-disciplinary team to focus on key areas of interest and the required capabilities. To provide
a reusable set of IT services we have broken down our platform to focus on the Ingestion, Digestion, Extraction and Analysis of data. In this presentation, we will outline how we brought focus and prioritization to our data sciences needs, our data sciences architecture, lessons learned and our future direction.
11:35 Data Experts: Improving Sponsored by
Translational Drug-Development Efficiency
Jamie MacPherson, Ph.D., Consultant, Tessella
We report on a novel approach to translational informatics support: embedding Data Experts’ within drug-project teams. Data experts combine first-line
informatics support and Business Analysis. They help teams exploit data sources that are diverse in type, scale and quality; analyse user-requirements and prototype potential software solutions. We then explore scaling this approach from a specific drug development team to all.
PLENARY KEYNOTE PRESENTATIONS: THURSDAY, MAY 1 | 8:00 – 10:00 AM @ BioIT World, April 29 – May 1, 2014 Seaport World Trade Center, Boston, MA
Reporter: Aviva Lev-Ari, PhD, RN
Keynote Introduction: Sponsored by Fred Lee, M.D., MPH, Director, Healthcare Strategy and Business Development, Oracle Health Sciences
Heather Dewey-Hagborg
Artist, Ph.D. Student, Rensselaer Polytechnic Institute
Heather Dewey-Hagborg is an interdisciplinary artist, programmer and educator who explores art as research and public inquiry. She recreates identity from strands of human hair in an entirely different way. Collecting hairs she finds in random public places – bathrooms, libraries, and subway seats – she uses a battery of newly developing technologies to create physical, life-sized portraits of the owners of these hairs. Her fixation with a single hair leads her to controversial art projects and the study of genetics. Traversing media ranging from algorithms to DNA, her work seeks to question fundamental assumptions underpinning perceptions of human nature, technology and the environment. Examining culture through the lens of information, Heather creates situations and objects embodying concepts, probes for reflection and discussion. Her work has been featured in print, television, radio, and online. Heather has a BA in Information Arts from Bennington College and a Masters degree from the Interactive Telecommunications Program at Tisch School of the Arts, New York University. She is currently a Ph.D. student in Electronic Arts at Rensselaer Polytechnic Institute.
Yaniv Erlich, Ph.D.
Principal Investigator and Whitehead Fellow, Whitehead Institute for Biomedical Research
Dr. Yaniv Erlich is Andria and Paul Heafy Family Fellow and Principal Investigator at the Whitehead Institute for Biomedical Research. He received a bachelor’s degree from Tel-Aviv University, Israel and a PhD from the Watson School of Biological Sciences at Cold Spring Harbor Laboratory in 2010. Dr. Erlich’s research interests are computational human genetics. Dr. Erlich is the recipient of the Burroughs Wellcome Career Award (2013), Harold M. Weintraub award (2010), the IEEE/ACM-CS HPC award (2008), and he was selected as one of 2010 Tomorrow’s PIs team of Genome Technology.
Isaac Samuel Kohane, M.D., Ph.D.
Henderson Professor of Health Sciences and Technology, Children’s Hospital and Harvard Medical School;
Director, Countway Library of Medicine; Director, i2b2 National Center for Biomedical Computing;
Co-Director, HMS Center for Biomedical Informatics
Isaac Kohane, MD, PhD, co-directs the Center for Biomedical Informatics at Harvard Medical School. He applies computational techniques, whole genome analysis, and functional genomics to study human diseases through the developmental lens, and particularly through the use of animal model systems. Kohane has led the use of whole healthcare systems, notably in the i2b2 project, as “living laboratories” to drive discovery research in disease genomics (with a focus on autism) and pharmacovigilance
(including providing evidence for the cardiovascular risk of hypoglycemic agents which ultimately contributed to “black box”ing by the FDA) and comparative effectiveness with software and methods adopted in over 84 academic health centers internationally. Dr. Kohane has published over 200 papers in the medical literature and authored a widely used book on Microarrays for an Integrative Genomics. He has been elected to multiple honor societies including the American Society for Clinical Investigation, the American College of Medical Informatics, and the Institute of Medicine. He leads a doctoral program in genomics and bioinformatics within the Division of Medical Science at Harvard University. He is also an occasionally practicing pediatric endocrinologist.
Track 5 Next-Gen Sequencing Informatics: Advances in Analysis and Interpretation of NGS Data @ BioIT World, April 29 – May 1, 2014 Seaport World Trade Center, Boston, MA
Reporter: Aviva Lev-Ari, PhD, RN
NGS Bioinformatics Marketplace: Emerging Trends and Predictions
10:50 Chairperson’s Remarks
Narges Baniasadi, Ph.D., Founder & CEO, Bina Technologies, Inc.
11:00 Global Next-Generation Sequencing Informatics Markets: Inflated Expectations in an Emerging Market
Greg Caressi, Senior Vice President, Healthcare and Life Sciences, Frost & Sullivan
This presentation evaluates the global next-generation sequencing (NGS) informatics markets from 2012 to 2018. Learn key market drivers and restraints,
key highlights for many of the leading NGS informatics services providers and vendors, revenue forecasts, and the important trends and predictions that
affect market growth.
Organizational Approaches to NGS Informatics
11:30 High-Performance Databases to Manage and Analyze NGS Data
Joseph Szustakowski, Ph.D., Head, Bioinformatics, Biomarker Development,
Novartis Institutes for Biomedical Research
The size, scale, and complexity of NGS data sets call for new data management and analysis strategies. High-performance database systems
combine the advantages of both established and cutting edge technologies. We are using high performance database systems to manage and analyze NGS, clinical, pathway, and phenotypic data with great success. We will describe our approach and concrete success stories that demonstrate its efficiency and effectiveness.
12:00 pm Taming Big Science Data Growth with Converged Infrastructure
Aaron D. Gardner, Senior Scientific Consultant,
BioTeam, Inc.
Many of the largest NGS sites have identified IO bottlenecks as their number one concern in growing their infrastructure to support current and projected
data growth rates. In this talk Aaron D. Gardner, Senior Scientific Consultant, BioTeam, Inc. will share real-world strategies and implementation details
for building converged storage infrastructure to support the performance, scalability and collaborative requirements of today’s NGS workflows.
12:15 Next Generation Sequencing: Workflow Overview from a High-Performance Computing Point of View
Carlos P. Sosa, Ph.D., Applications Engineer, HPC Lead,
Cray, Inc.
Next Generation Sequencing (NGS) allows for the analysis of genetic material with unprecedented speed and efficiency. NGS increasingly shifts the burden
from chemistry done in a laboratory to a string manipulation problem, well suited to High- Performance Computing. We explore the impact of the NGS
workflow in the design of IT infrastructures. We also present Cray’s most recent solutions for NGS workflow.
SOSA in REAL TIME
Bioinformatics and BIG DATA – NGS @ CRAY i 2014
I/O moving, storage data – UNIFIED solution by Cray
Data access
Fast Access
Storage
manage high performance computinf; NGS work flow, multiple human genomes 61 then 240 sequentiallt, with high performance in 51 hours, 140 genomes in simultaneous
Architecture @Cray for Genomics
sequensors
Galaxy
servers for analysis
workstation: Illumina, galaxy, CRAY does the integration of 3rd party SW using a workflow LEVERAGING the network, the fastest in the World, network useding NPI for scaling and i/O
Compute blades, reserves formI?O nodes, the Fastest interconnet in the industry
scale of capacity and capability, link interconnect in the file System: lustre
optimization of bottle neck: capability, capacity, file structure for super fast I/O
12:40 Luncheon Presentation I
Erasing the Data Analysis Bottleneck with BaseSpace
Jordan Stockton, Ph.D., Marketing Director,
Enterprise Informatics, Illumina, Inc.
Since the inception of next generation sequencing, great attention has been paid to challenges such as storage, alignment, and variant calling. We believe
that this narrow focus has distracted many biologists from higher-level scientific goals, and that simplifying this process will expedite the discovery
process in the field of applied genomics. In this talk we will show that applications in BaseSpace can empower a new class of researcher to go from
sample to answer quickly, and can allow software developers to make their tools accessible to a vast and receptive audience.
1:10 Luncheon Presentation II: Sponsored by
The Empowered Genome Community: First Insights from Shareable Joint Interpretation of Personal Genomes for Research
Nathan Pearson, Ph.D. Principal Genome Scientist,
QIAGEN
Genome sequencing is becoming prevalent however understanding each genome requires comparing many genomes. We launched the Empowered Genome Community, consisting of people from programs such as the Personal Genome Project (PGP) and Illumina’s Understand Your Genome. Using Ingenuity Variant Analysis, members have identified proof of principle insights on a common complex disease (here,myopia) derived by open collaborative analysis of PGP genomes.
Pearson in REAL TIME
One Genome vs. population of Genomes
IF one Genome:
ancestry
family health
less about drug and mirrors
health is complex
CHallenges
1. mine genome
2. what all genome swill do for Humanity not what my genome can do for me
Track 4 Bioinformatics: Utilizing Massive Quantities of –omic Information across Research Initiatives @ BioIT World, April 29 – May 1, 2014 Seaport World Trade Center, Boston, MA
Reporter: Aviva Lev-Ari, PhD, RN
Bioinformatics for Big Data
10:50 Chairperson’s Remarks
Les Mara, Founder, Databiology, Ltd.
11:00 Data Management Best Practices for Genomics Service Providers
Vas Vasiliadis, Director, Products, Computation Institute,
University of Chicago and Argonne National Laboratory
Genomics research teams in academia and industry are increasingly limited at all stages of their work by large and unwieldy datasets, poor integration between the computing facilities they use for analysis, and difficulty in sharing analysis results with their customers and collaborators. We will discuss issues with current approaches and describe emerging best practices for managing genomics data through its lifecycle.
Vas in REAL TIME
Computation Institute @ University of Chicago solutions to non profit entities, scale and make available in an affordable way “I have nothing to say on Big Data”, 57.7% survey by NAS, average time researcher spend on research, it will get worse, research data management morphed into better ways, industrial robust way, commercial start ups are role model. All functions of an enterprise now available as applications for small business.
Highly scaleable, invisible
high performance
In Genomics, tools – shipping hard drive new ways to develop research infrastructure:
dropbox, does not scale Amazon’s Webservices is the cloud
security in sharing across campuses, InCommon – cross domains sw access constrains are mitigated.
identity provision for multiple identity – identity Hub, one time association done, Group Hubs, i.e., ci connect – UChicago, access to systems at other campuses – connecting science to cycles of data, network not utilizied efficiently – tools not design for that, FTP, Firewalls are designed for data not Big data.
Science DMZ – carve realestate for Science data transfer, monitoring the transfer
11:30 NGS Analysis to Drug Discovery: Impact of High-Performance Computing in Life Sciences
Bhanu Rekepalli, Ph.D., Assistant Professor and Research Scientist, Joint Institute for Computational Sciences, The University of Tennessee, Oak Ridge National Laboratory
We are working with small-cluster-based applications most widely used by the scientific community on the world’s premier supercomputers. We incorporated these parallel applications into science gateways with user-friendly, web-based portals. Learn how the research at UTK-ORNL will help to bridge the gap between the rate of big data generation in life sciences and the speed and ease at which biologists and pharmacists can study this data.
Bhanu in REAL TIME
Cost per Genome does down, 2011 from $100,000 to $1,000
Solutions:
architecture
parallel informatics
SW modules
web-based gateway
XSEDE.org sponsured by NSF at all sponsored research by NSF
LCF – applications: Astrophysics, Bioinfo, CFD, highly scalable wrappers for the analysis Blast scaling results in Biology
Next generation super computers: Xeon/Phi
NICS Informatics Science gateway – PoPLAR Portal for Parallel Scaling Life Sciences Applications & Research
automated workflows
Smithsonian Institute, generate genomes fro all life entities in the universe: BGI
Titan Genomic Data analysis – Everglade ecosystem, sequenced
Univ S. Carolina great computing infrastructure
Super computer: KRAKEN
5-10 proteins modeling on supercomputers for novel drug discovery
Vascular Tree system for Heart transplant – visualization and modeling
12:00 pm The Future of Biobank Informatics
Bruce Pharr, Vice President, Product Marketing, Laboratory Systems, Remedy Informatics
As biobanks become increasingly essential to basic, translational, and clinical research for genetic studies and personalized medicine, biobank informatics must address areas from biospecimen tracking, privacy protection, and quality management to pre-analytical and clinical collection/identification of study data elements. This presentation will examine specific requirements for third-generation biobanks and how biobank informatics will meet those requirements.
Bruce Pharr in REAL TIME
Flexible Standartization
BioBank use of informatics in the1980s – bio specimens. 1999 RAND research 307 M biospecimens in US biobanks growing at 20M per year.
2nd – Gen Bioband
2005 – 3rd-Gen Biobanks – 15000 studies on Cancer, biospecimen, Consent of donors is a must.
Registries set up the storage: administrator dashboard vs user bashboard
2. Interoperability
3. Quality analysis
4. Informed Consent
12:15 Learn How YarcData’s Graph Analytics Appliance Makes It Easy to Use Big Data in Life Sciences
Ted Slater, Senior Solutions Architect, Life Sciences, YarcData, a division of Cray
YarcData, a division of Cray, offers high performance solutions for big data graph analytics at scale, finally giving researchers the power to leverage all the data they need to stratify patients, discover new drug targets, accelerate NGS analysis, predict biomarkers, and better understand diseases and their treatments.
12:40 Luncheon Presentation I
The Role of Portals for Managing Biostatistics Projects at a CRO
Les Jordan, Director, Life Sciences IT Consulting, Quintiles
This session will focus on how portals and other tools are used within Quintiles and at other pharmas to manage projects within the biostatistics department.
1:10 Luncheon Presentation II (Sponsorship Opportunity Available) or Lunch on Your Own
1:50 Chairperson’s Remarks
Michael Liebman, Ph.D., Managing Director, IPQ Analytics, LLC
Sabrina Molinaro, Ph.D., Head of Epidemiology, Institute of ClinicalPhysiology, National Research Council –
CNR Italy
1:55 Integration of Multi-Omic Data Using Linked Data Technologies
Aleksandar Milosavljevic, Ph.D., Professor, Human Genetics; Co-Director,
Program in Structural & Computational Biology and Molecular Biophysics;
Co-Director, Computational and Integrative Biomedical Research Center,
Baylor College of Medicine
By virtue of programmatic interoperability (uniform REST APIs), Genboree servers enable virtual integration of multi-omic data that is distributed across multiple physical locations. Linked Data technologies of the Semantic Web provide an additional “logical” layer of integration by enabling distributed queries across the distributed data and by bringing multi-omic data into the context of pathways and other background knowledge required for data interpretation.
2:25 Building Open Source Semantic Web-Based Biomedical Content Repositories to Facilitate and Speed Up Discovery and Research
Bhanu Bahl, Ph.D., Director, Clinical and Translational Science Centre,
Harvard Medical School
Douglas MacFadden, CIO, Harvard Catalyst at Harvard Medical School
Eagle-i open source network at Harvard provides a state-of-the-art informatics
AWARDS: Best of Show Awards, Best Practices Awards and 2014 Benjamin Franklin Award @ BioIT World, April 29 – May 1, 2014 Seaport World Trade Center, Boston, MA
Reorter: Aviva Lev-Ari, PhD, RN
Best of Show Awards
The Best of Show Awards offer exhibitors an opportunity to distinguish their products from the competition. Judged by a team of leading industry experts and Bio-IT World editors, this award identifies exceptional innovation in technologies used by life science professionals today. Judging and the announcement of winners is conducted live in the Exhibit Hall. Winners will be announced on Wednesday, April 30 at 5:30pm. The deadline for product submissions is February 21, 2014. To learn more about this program, contact Ryan Kirrane at 781-972-1354 or email rkirrane@healthtech.com.
2014 WINNER(s) are announced in Real Time
2014 – Five categories
1. Clinical ad Health IT – Astazeneca with Tessella – Real Time Analytics for Clinical Trial (RTACT) – engine for innovations
2. Research and Drug Discovery: U-bioPRED with the TranSMART Foundation – Open Source – Emperial College – Biomarkers for Asthma, hospitals, 340 universities, 34 Pharmas
3. Informatics: Pistoia Alliance – HELM – Pfizer, released data for HELM Project
4. Knowledge Management Finalists: GENENTECH – Genentech Cell Line Resource
5. IT Infrastructure/HPC Winner:
Baylor College of Medicine with DNAnexus –
2014 Judges’Prize – UK for Patient Data Intgration
2014 Editors’ Choice Award: Mount Sinai – Rethinking Type 2 Diabetes through Data Informatics
2014 Benjamin Franklin Award
The Benjamin Franklin Award for Open Access in the Life Sciences is a humanitarian/bioethics award presented annually by the Bioinformatics Organization to an individual who has, in his or her practice, promoted free and open access to the materials and methods used in the life sciences. Nominations are now being accepted!
The winner will be announced in the Ampitheater at 9:00am on Wednesday, April 30 during the Plenary Keynote and Awards Program, WEDNESDAY, APRIL 30 | 8:00 – 9:45 AM.
1960 – Early structure of proteins: Myoglobin, hemoglobin
1970
1980
1990
2000 Ribosomes
2010s: macromolecule machines
Science of protein structure
Technology: electromicroscopy, Structure Genomics – data driven science Hybrid methods at Present for 3D structure identification
COMMUNITY ATTITUDE – 1971 PDB archive established at Cold Spring Harbor, Walter Hamilton, petition to have an Open DB of Protein, Brookhaven Labs, to be shared with UK, Nature New Biology: Seven Structures to the DB
1982 – AIDs epidemic – NIH – requested data to be Open, community set its own rules on data organization Fred Richards, Yale, requested on moral ground, DB to be Open.
1993 – mandatory to sahre dat linked to publication, no Journal will accet an article id data was not in PDB.
1996 – dictionary put together
2008: experimental data madatory to be put in PDB, Validation
2011: PDBx definition of X-Ray, NMR, and 3DEM, small-angle Scattering
Collaboration with to enable: self storage, structure based drug design
SCIENCE in ther IMPORTANT to be put there, IT evolved, changes to data
global organization collaboration
Communities to work together
L.D>Bernal – SOcial function of Science, 1939
Elenor Ostrom 2009 Nobel Prize in Economics – Community collaboration by rules
Best Practices Awards
Add value to your Conference & Expo attendance, sponsorship or exhibit package, and further heighten your visibility with the creative positioning offered as a Best Practices participant. Winners will be selected by a peer review expert panel in early 2014.
Bio-IT World will present the Awards in the Amphitheater at 9:30am on Wednesday, April 30 during the Plenary Keynote and Awards Program, WEDNESDAY, APRIL 30 | 8:00 – 9:45 AM
Early bird deadline (no fee) for entry is December 16, 2013 and final deadline (fee) for entry is February 10, 2014. Full details including previous winners and entry forms are available at Bio-ITWorldExpo.com.
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22